1. Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N‐Road study. (6th April 2020) Authors: Nishiwaki, Kaichi; Sugimoto, Kei‐ji; Tamaki, Shigehisa; Hisatake, Junichi; Yokoyama, Hisayuki; Igarashi, Tadahiko; Shinagawa, Atsushi; Sugawara, Takeaki; Hara, Satoru; Fujikawa, Kazuhisa; Shimizu, Seiichi; Yujiri, Toshiaki; Tojo, Arinobu; Wakita, Hisashi Journal: Cancer medicine Issue: Volume 9:Number 11(2020) Page Start: 3742 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and efficacy of romiplostim in patients with eltrombopag‐resistant or ‐intolerant immune thrombocytopenia. (17th July 2013) Authors: Tsukamoto, Shokichi; Nakaseko, Chiaki; Takeuchi, Masahiro; Kumagai, Kyoya; Komatsu, Tsunehiko; Tanaka, Hiroaki; Hara, Satoru; Koizumi, Masayuki; Imai, Hidenori; Yokota, Akira; Takeuchi, Masami; Inokuchi, Koiti; Matsuura, Yasuhiro; Aotsuka, Nobuyuki; Wakita, Hisashi Journal: British journal of haematology Issue: Volume 163:Number 2(2013:Oct.) Page Start: 286 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗